Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYMR NYSE:NUVB NASDAQ:PTGX NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$81.420.0%$83.33$28.50▼$103.00$6.70B2.06457,042 shs587,343 shsNUVBNuvation Bio$4.76+0.2%$4.62$1.57▼$9.75$1.65B1.514.32 million shs4.20 million shsPTGXProtagonist Therapeutics$99.56-0.8%$101.73$45.43▼$107.84$6.46B1.89489,182 shs597,774 shsSYRESpyre Therapeutics$73.50+1.9%$63.60$13.93▼$78.80$6.26B3.12978,584 shs1.11 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics-0.05%+3.21%-0.11%-10.87%+182.71%NUVBNuvation Bio+0.49%+0.74%+9.55%-19.53%+117.35%PTGXProtagonist Therapeutics-0.85%+0.37%+1.06%+8.12%+117.62%SYRESpyre Therapeutics+1.93%-0.74%+2.24%+70.89%+387.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$81.420.0%$83.33$28.50▼$103.00$6.70B2.06457,042 shs587,343 shsNUVBNuvation Bio$4.76+0.2%$4.62$1.57▼$9.75$1.65B1.514.32 million shs4.20 million shsPTGXProtagonist Therapeutics$99.56-0.8%$101.73$45.43▼$107.84$6.46B1.89489,182 shs597,774 shsSYRESpyre Therapeutics$73.50+1.9%$63.60$13.93▼$78.80$6.26B3.12978,584 shs1.11 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics-0.05%+3.21%-0.11%-10.87%+182.71%NUVBNuvation Bio+0.49%+0.74%+9.55%-19.53%+117.35%PTGXProtagonist Therapeutics-0.85%+0.37%+1.06%+8.12%+117.62%SYRESpyre Therapeutics+1.93%-0.74%+2.24%+70.89%+387.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYMRKymera Therapeutics 2.95Moderate Buy$118.1045.04% UpsideNUVBNuvation Bio 2.55Moderate Buy$12.50162.61% UpsidePTGXProtagonist Therapeutics 2.88Moderate Buy$115.2115.72% UpsideSYRESpyre Therapeutics 3.00Buy$90.2522.79% UpsideCurrent Analyst Ratings BreakdownLatest NUVB, KYMR, SYRE, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026NUVBNuvation Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$135.005/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$135.005/15/2026PTGXProtagonist Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/12/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.005/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026SYRESpyre Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$92.00 ➝ $107.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.005/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.005/6/2026PTGXProtagonist Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $118.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYMRKymera Therapeutics$39.21M170.81N/AN/A$18.72 per share4.35NUVBNuvation Bio$62.90M26.35N/AN/A$0.92 per share5.17PTGXProtagonist Therapeutics$74.06M86.45N/AN/A$10.19 per share9.77SYRESpyre Therapeutics$890K7,171.62N/AN/A$5.93 per share12.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%8/6/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)Latest NUVB, KYMR, SYRE, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million3/2/2026Q4 2025NUVBNuvation Bio-$0.11-$0.11N/A-$0.11$36.82 million$41.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKYMRKymera TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYMRKymera TherapeuticsN/A10.8110.81NUVBNuvation Bio0.157.447.24PTGXProtagonist TherapeuticsN/A17.7617.76SYRESpyre TherapeuticsN/A8.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYMRKymera TherapeuticsN/ANUVBNuvation Bio61.67%PTGXProtagonist Therapeutics98.63%SYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipKYMRKymera Therapeutics15.98%NUVBNuvation Bio30.11%PTGXProtagonist Therapeutics5.19%SYRESpyre Therapeutics15.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableNUVBNuvation Bio60348.20 million243.36 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableSYRESpyre Therapeutics7386.84 million73.22 millionOptionableNUVB, KYMR, SYRE, and PTGX HeadlinesRecent News About These CompaniesSeven Grand Managers LLC Buys Shares of 100,000 Spyre Therapeutics, Inc. $SYREMay 28 at 6:38 AM | marketbeat.comSpyre Therapeutics to Participate in Upcoming June Investor ConferencesMay 26, 2026 | globenewswire.comPSP Research LLC Takes Position in Spyre Therapeutics, Inc. $SYREMay 20, 2026 | marketbeat.comLifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)May 18, 2026 | theglobeandmail.comUBS Group AG Has $22.30 Million Stake in Spyre Therapeutics, Inc. $SYREMay 12, 2026 | marketbeat.comVanguard Group Inc. Has $132.19 Million Stock Position in Spyre Therapeutics, Inc. $SYREMay 12, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Invests $547,000 in Spyre Therapeutics, Inc. $SYREMay 12, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year High - Time to Buy?May 11, 2026 | marketbeat.comF m Investments LLC Acquires 48,825 Shares of Spyre Therapeutics, Inc. $SYREMay 10, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Director Sells $5,952,000.00 in StockMay 9, 2026 | insidertrades.comMichael Thomas Henderson Sells 80,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockMay 8, 2026 | marketbeat.comSpyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $97.00 at CitigroupMay 6, 2026 | marketbeat.comSpyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for StockholdersMay 6, 2026 | tipranks.comSpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5, 2026 | globenewswire.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $892,125.00 in StockMay 2, 2026 | insidertrades.comSpyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million RaiseMay 1, 2026 | finance.yahoo.comInsider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 12,500 Shares of StockMay 1, 2026 | marketbeat.comInsider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of StockMay 1, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in StockMay 1, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3% - Here's What HappenedMay 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNUVB, KYMR, SYRE, and PTGX Company DescriptionsKymera Therapeutics NASDAQ:KYMR$81.42 -0.04 (-0.05%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$81.39 -0.03 (-0.04%) As of 05/29/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Nuvation Bio NYSE:NUVB$4.76 +0.01 (+0.21%) Closing price 05/29/2026 03:59 PM EasternExtended Trading$4.70 -0.06 (-1.34%) As of 05/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Protagonist Therapeutics NASDAQ:PTGX$99.56 -0.85 (-0.85%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$99.61 +0.05 (+0.05%) As of 05/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Spyre Therapeutics NASDAQ:SYRE$73.50 +1.39 (+1.93%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$74.22 +0.72 (+0.99%) As of 05/29/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
